SFTA3 | Surfactant associated 3 | | | | |
|
| | Group enriched | 555 |
NKX2-1 | NK2 homeobox 1 | | | | |
|
| | Group enriched | 107 |
CLDN18 | Claudin 18 | | | | |
|
| | Group enriched | 54 |
SCN1A | Sodium channel, voltage-gated, type I, alpha subunit | | | | |
|
| | Group enriched | 40 |
CCDC37 | Coiled-coil domain containing 37 | | | | |
|
| | Group enriched | 28 |
DNAH12 | Dynein, axonemal, heavy chain 12 | | | | |
|
| | Group enriched | 17 |
CHIT1 | Chitinase 1 (chitotriosidase) | | | | |
|
| | Group enriched | 14 |
CHIA | Chitinase, acidic | | | | |
|
| | Group enriched | 13 |
DLEC1 | Deleted in lung and esophageal cancer 1 | | | | |
|
| Cytoplasm | Group enriched | 12 |
RASGRF1 | Ras protein-specific guanine nucleotide-releasing factor 1 | | | | |
|
| Golgi apparatus | Group enriched | 11 |
WDR96 | WD repeat domain 96 | | | | | |
| Nucleus | Group enriched | 11 |
FCN3 | Ficolin (collagen/fibrinogen domain containing) 3 | | | | |
|
| | Group enriched | 10 |
GGTLC1 | Gamma-glutamyltransferase light chain 1 | | | | |
|
| | Group enriched | 10 |
SEC14L4 | SEC14-like 4 (S. cerevisiae) | | | | | |
| | Group enriched | 10 |
AQP4 | Aquaporin 4 | | | | |
|
| Plasma membrane Cell Junctions | Group enriched | 9 |
CACNG4 | Calcium channel, voltage-dependent, gamma subunit 4 | | | | |
|
| | Group enriched | 9 |
DNAAF1 | Dynein, axonemal, assembly factor 1 | | | | |
|
| Plasma membrane Cytoplasm Nucleus | Group enriched | 9 |
RP11-664D7.4 | HCG1787533; Uncharacterized protein | | | | |
|
| | Group enriched | 9 |
SERTM1 | Serine-rich and transmembrane domain containing 1 | | | | |
|
| | Group enriched | 8 |
SLC46A2 | Solute carrier family 46, member 2 | | | | |
|
| | Group enriched | 8 |
SLC6A4 | Solute carrier family 6 (neurotransmitter transporter), member 4 | | | | | |
| | Group enriched | 8 |
UPK3B | Uroplakin 3B | | | | |
|
| | Group enriched | 8 |
C19orf59 | Chromosome 19 open reading frame 59 | | | | |
|
| | Group enriched | 7 |
ICAM5 | Intercellular adhesion molecule 5, telencephalin | | | | |
|
| Nucleus but not nucleoli | Group enriched | 7 |
KHDC3L | KH domain containing 3-like, subcortical maternal complex member | | | | |
|
| | Group enriched | 7 |
PLA2G4F | Phospholipase A2, group IVF | | | | |
|
| | Group enriched | 7 |
SLC22A31 | Solute carrier family 22, member 31 | | | | | |
| | Group enriched | 7 |
ACE | Angiotensin I converting enzyme | | | | |
|
| | Group enriched | 6 |
ADCY8 | Adenylate cyclase 8 (brain) | | | | |
|
| | Group enriched | 6 |
BPIFA1 | BPI fold containing family A, member 1 | | | | |
|
| | Group enriched | 6 |
C10orf67 | Chromosome 10 open reading frame 67 | | | | |
|
| | Group enriched | 6 |
FRMPD2 | FERM and PDZ domain containing 2 | | | | |
|
| | Group enriched | 6 |
SDR16C5 | Short chain dehydrogenase/reductase family 16C, member 5 | | | | |
|
| | Group enriched | 6 |
TBX5 | T-box 5 | | | | |
|
| | Group enriched | 6 |
WNT3A | Wingless-type MMTV integration site family, member 3A | | | | |
|
| | Group enriched | 6 |
ACOXL | Acyl-CoA oxidase-like | | | | |
|
| | Group enriched | 5 |
AGTR2 | Angiotensin II receptor, type 2 | | | | |
|
| | Group enriched | 5 |
CAPN13 | Calpain 13 | | | | |
|
| | Group enriched | 5 |
CEACAM6 | Carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) | | | | |
|
| | Group enriched | 5 |
CLIC3 | Chloride intracellular channel 3 | | | | |
|
| Nucleus Cytoplasm | Group enriched | 5 |
DNAH10 | Dynein, axonemal, heavy chain 10 | | | | |
|
| | Group enriched | 5 |
FFAR4 | Free fatty acid receptor 4 | | | | |
|
| | Group enriched | 5 |
PLA2G3 | Phospholipase A2, group III | | | | |
|
| | Group enriched | 5 |
SCGB3A1 | Secretoglobin, family 3A, member 1 | | | | | |
| | Group enriched | 5 |
SHC3 | SHC (Src homology 2 domain containing) transforming protein 3 | | | | |
|
| | Group enriched | 5 |
SULT1A2 | Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 2 | | | | |
|
| | Group enriched | 5 |
TCTEX1D1 | Tctex1 domain containing 1 | | | | |
|
| | Group enriched | 5 |
TREM1 | Triggering receptor expressed on myeloid cells 1 | | | | |
|
| | Group enriched | 5 |